You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Epidermal growth factor receptor mutation positive (EGFRm)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Beijing (Icotinib, Cisplatin, Carboplatin)

Recruiting
  • Non-Small Cell Lung Cancer
  • Beijing, China
    BeijingCancerH
Nov 2, 2021

NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 24, 2023

Central Nervous System Metastatic EGFR Mutation Positive NSCLC

Not yet recruiting
  • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 6, 2023

    Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7

    Active, not recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +5 more
    • Laboratory Biomarker Analysis
    • +3 more
    • New Haven, Connecticut
    • +4 more
    Jan 27, 2023

    Breast Cancer Invasive Trial (pyrotinib)

    Not yet recruiting
    • Breast Cancer Invasive
    • (no location specified)
    Jun 18, 2023

    Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

    Recruiting
    • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
    • Canton, Ohio
      Gabrail Cancer and Research Center
    Jul 21, 2023

    NSCLC Trial in Spain, United Kingdom, United States (Lazertinib)

    Completed
    • Carcinoma, Non-Small-Cell Lung
    • Duarte, California
    • +8 more
    Jan 31, 2023

    Real-world Data of Afatinib Treatment in First-line Setting and

    Active, not recruiting
    • Non-squamous, Non-Small Cell Lung Cancer
    • Tokyo, Japan
      Nippon Boehringer Ingelheim Co., Ltd.
    Jan 9, 2023

    Breast Cancer Trial in Sarasota, Nashville (AC699)

    Recruiting
    • Breast Cancer
    • Sarasota, Florida
    • +1 more
    Jan 3, 2023

    Learn About Dacomitnib in Non-small Cell Lung Cancer Which Has

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • (no location specified)
    Oct 4, 2023

    Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

    Recruiting
    • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jun 12, 2023

    Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T

    Not yet recruiting
    • Recurrent Glioblastoma
    • Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
    • (no location specified)
    Apr 4, 2023

    Breast Cancer Trial in Beijing, Zhengzhou, Changsha (EG017)

    Not yet recruiting
    • Breast Cancer
    • Beijing, Benjing, China
    • +2 more
    Dec 30, 2022

    Observes Afatinib as First-line Treatment and Sequential Therapy

    Active, not recruiting
    • Non-squamous, Non-Small Cell Lung Cancer
    • Beijing, China
    • +9 more
    Jan 9, 2023

    Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

    Recruiting
    • Metastatic Breast Cancer
    • +2 more
    • Ocala, Florida
      Ocala Oncology Center PL DBA Florida Cancer Affiliates
    Jul 19, 2023

    NSCLC Trial in Australia, China, Korea, Republic of (AZD9291)

    Active, not recruiting
    Has Results
    • Non-Small Cell Lung Cancer
    • Kogarah, Australia
    • +29 more
    Oct 20, 2022

    OPTImal PALliative Anti-epidermal Growth Factor Receptor

    Active, not recruiting
    • Colorectal Cancer Metastatic
    • +5 more
    • Plasma circulating DNA analysis
    • Aarhus, Denmark
      Aarhus University Hospital
    Feb 24, 2022

    HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

    Recruiting
    • HR+/HER2- Advanced Breast Cancer
    • Targeted Therapy
    • Beijing, Beijing, China
      National Cancer Center/National Clinical Research Center for Can
    Aug 1, 2023

    Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

    Recruiting
    • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
    • Canton, Ohio
      Gabrail Cancer and Research Center
    Jul 25, 2023

    Breast Cancer Trial (Tucatinib, Doxil)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Feb 17, 2023

    Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

    Recruiting
    • Locally Advanced or Unresectable Metastatic Breast Cancer
    • Stage IV Breast Cancer
    • Sacituzumab Govitecan-hziy
    • +3 more
    • Marietta, Georgia
    • +1 more
    Apr 21, 2023

    Breast Tumors Trial in Chuo Ku, Koto-Ku (H3B-6545, Antihistamine)

    Active, not recruiting
    • Breast Neoplasms
    • Chuo Ku, Japan
    • +1 more
    Dec 19, 2022

    Breast Cancer, Breast Cancer, Early-Onset Trial (Giredestrant, Tamoxifen)

    Not yet recruiting
    • Breast Cancer
    • Breast Cancer, Early-Onset
    • (no location specified)
    Jan 18, 2023

    EGFR Mutation-Related Tumors Trial (NX-019)

    Not yet recruiting
    • EGFR Mutation-Related Tumors
    • (no location specified)
    Aug 22, 2022

    NSCLC Trial in Qingdao (osimertinib oral and bevazizumab intravenously)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • osimertinib oral and bevazizumab intravenously
    • Qingdao, Shandong, China
      Qingdao Central Hospital, Qingdao Cancer Hospital
    Nov 1, 2021